About Us
The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford. The OPDC was established in February 2010 and brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.
Our world-class research centre works to understand the earliest events in the development of Parkinson’s with an ultimate view to target the molecular mechanisms of disease with neuroprotective therapies to prevent disease onset or delay progression.
Our program is focused on the molecular pathways to Parkinson’s in order to:
- Predict the onset of Parkinson’s
- Understand the progression of Parkinson’s
- Identify potential drug targets for Parkinson's
- Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
Watch the video below to learn more about OPDC's research:
Latest News
Upcoming Seminars
-
Tuesday, 03 June 2025, 9am to 5.30pm
-
Monday, 23 June 2025, 12pm to 1pm
Speakers: Associate Professor Antony Cooper
Latest publications
-
Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes.
Journal article
Hu MT. et al, (2025), Brain
-
Association of cholesterol and glycemic state biomarkers with phenotypic variation and Parkinson's disease progression: The Oxford Discovery cohort.
Journal article
Ho Chiu NK. et al, (2025), J Parkinsons Dis
-
Heritable maintenance of chromatin modifications confers transcriptional memory of interferon-γ signaling.
Journal article
Mikulski P. et al, (2025), Nat Struct Mol Biol
-
Recent developments in gene therapy for Parkinson's disease.
Journal article
Szunyogh S. et al, (2025), Mol Ther
-
An axonal brake on striatal dopamine output by cholinergic interneurons.
Journal article
Zhang Y-F. et al, (2025), Nat Neurosci
-
Single extracellular vesicle detection assay identifies membrane-associated α-synuclein as an early-stage biomarker in Parkinson's disease.
Journal article
Yan S. et al, (2025), Cell Rep Med